These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 25243157)

  • 1. Ergotamine and nicergoline - facts and myths.
    Zajdel P; Bednarski M; Sapa J; Nowak G
    Pharmacol Rep; 2015 Apr; 67(2):360-3. PubMed ID: 25712664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A unique and promising combination of medications for the treatment of Alzheimer's disease.
    Weinstein JD
    Med Hypotheses; 2017 Nov; 109():53-55. PubMed ID: 29150293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of nicergoline treatment in Parkinson's disease associated with dementia.
    Lee S; Na SH; Chung YA; Jeong H; Song IU
    J Clin Neurosci; 2019 Dec; 70():136-139. PubMed ID: 31431403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. pH-driven colloidal transformations based on the vasoactive drug nicergoline.
    Salentinig S; Tangso KJ; Hawley A; Boyd BJ
    Langmuir; 2014 Dec; 30(49):14776-81. PubMed ID: 25409414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy and safety of nicergoline combined with oxiracetam in the treatment of vascular cognitive impairment.
    Wang B; Zhong L; Qiao P; Ma Z
    Pak J Pharm Sci; 2020 Jan; 33(1(Special)):417-422. PubMed ID: 32173636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The use nicergoline in the treatment of diabetes mellitus].
    Popova IV; Karpenko AA
    Angiol Sosud Khir; 2017; 23(3):39-46. PubMed ID: 28902812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Features and outcomes of drugs for combination therapy as multi-targets strategy to combat Alzheimer's disease.
    Sahoo AK; Dandapat J; Dash UC; Kanhar S
    J Ethnopharmacol; 2018 Apr; 215():42-73. PubMed ID: 29248451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in Regional Cerebral Perfusion after Nicergoline Treatment in Early Alzheimer's Disease: A Pilot Study.
    Im JJ; Jeong HS; Park JS; Yang Y; Na SH; Oh JK; Chung YA; Song IU
    Dement Neurocogn Disord; 2017 Dec; 16(4):104-109. PubMed ID: 30906380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nicergoline in senile dementia of Alzheimer type and multi-infarct dementia: a double-blind, placebo-controlled, clinical and EEG/ERP mapping study.
    Saletu B; Paulus E; Linzmayer L; Anderer P; Semlitsch HV; Grünberger J; Wicke L; Neuhold A; Podreka I
    Psychopharmacology (Berl); 1995 Feb; 117(4):385-95. PubMed ID: 7604138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ameliorative effect of nicergoline on cognitive function through the PI3K/AKT signaling pathway in mouse models of Alzheimer's disease.
    Zang G; Fang L; Chen L; Wang C
    Mol Med Rep; 2018 May; 17(5):7293-7300. PubMed ID: 29568940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indole-containing pharmaceuticals: targets, pharmacological activities, and SAR studies.
    Zeng W; Han C; Mohammed S; Li S; Song Y; Sun F; Du Y
    RSC Med Chem; 2024 Mar; 15(3):788-808. PubMed ID: 38516587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A clinical trial of nicergoline to prevent temporary threshold shift.
    Klamkam P; Pagcharoenpol R; Treesaranuwattana T; Silpsrikul P; Jaruchinda P; Wasuwat P; Suwannahitatorn P
    Laryngoscope Investig Otolaryngol; 2022 Apr; 7(2):515-522. PubMed ID: 35434325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholinesterase inhibitors for the treatment of dementia: real-life data in Hungary.
    Balázs N; Bereczki D; Ajtay A; Oberfrank F; Kovács T
    Geroscience; 2022 Feb; 44(1):253-263. PubMed ID: 34655009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sesame Oil-Based Nanostructured Lipid Carriers of Nicergoline, Intranasal Delivery System for Brain Targeting of Synergistic Cerebrovascular Protection.
    Abourehab MAS; Khames A; Genedy S; Mostafa S; Khaleel MA; Omar MM; El Sisi AM
    Pharmaceutics; 2021 Apr; 13(4):. PubMed ID: 33921796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphodiesterase Inhibitors for Alzheimer's Disease: A Systematic Review of Clinical Trials and Epidemiology with a Mechanistic Rationale.
    Sanders O; Rajagopal L
    J Alzheimers Dis Rep; 2020 Jun; 4(1):185-215. PubMed ID: 32715279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined network pharmacology and virtual reverse pharmacology approaches for identification of potential targets to treat vascular dementia.
    Lagunin AA; Ivanov SM; Gloriozova TA; Pogodin PV; Filimonov DA; Kumar S; Goel RK
    Sci Rep; 2020 Jan; 10(1):257. PubMed ID: 31937840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of nicergoline as an agent for management of cognitive function disorders.
    Saletu B; Garg A; Shoeb A
    Biomed Res Int; 2014; 2014():610103. PubMed ID: 25243157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic use of nicergoline.
    Winblad B; Fioravanti M; Dolezal T; Logina I; Milanov IG; Popescu DC; Solomon A
    Clin Drug Investig; 2008; 28(9):533-52. PubMed ID: 18666801
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.